Literature DB >> 26274557

[S3 Guideline. Part 1: Diagnosis and Differential Diagnosis of Non-Traumatic Adult Femoral Head Necrosis].

K Bohndorf1, J Beckmann2, M Jäger3, W Kenn4, U Maus5, U Nöth6, K M Peters7, C Rader8, S Reppenhagen9, A Roth10.   

Abstract

Non-traumatic femoral head necrosis (FHN) is primarily a disease of the middle-aged adult. Early diagnosis, at a time with lacking or minimal clinical symptoms, is mandatory to consider conservative therapy or joint preserving operations as a therapeutic option. The new German S3 guideline about diagnosis and therapy of FHN is a cooperative effort of five professional medical societies, overall headed by the Deutsche Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC). This review (part I/III) cites and explains the statements of the S3 guideline as agreed on the use of imaging methods for diagnosis of FHN. A diagnostic algorithm is presented. FHN clinically has to be considered in case of equivocal pain of a hip joint with a minimum of 6 weeks duration, when risk factors can be revealed, groin pain at clinical investigation, limping, pain or limitation of movement in case of load, and no obvious differential diagnoses. Is an FHN clinically suspected, primarily radiographs of the pelvis ap and a Lauenstein projection of the hip involved should be carried out. When the radiographs are normal, an MRI of the hips should follow routinely. MRI allows the diagnosis of FNH with high accuracy. Furthermore, MRI reveals the site and the size of the necrotic area involved and evaluates the integrity of the joint surface and subchondral fractures. When ARCO stage II (ARCO: Association Research Circulation Osseous) is diagnosed and MRI does not allow one to determine the joint surface with certainty, a CT of the hip joints should be performed. The S3 guideline explains and recommends the use of the ARCO classification. Although, this classification of 1993 is still largely based on radiographs, the pragmatic use of an "extended" version seems reasonable. Today, classical radiographic criteria like impression of the joint surface and subchondral fractures ("crescent sign") are better to be evaluated by MRI, in cases of subtle findings MRI is even surpassed by CT. The extent of the necrosis in the femoral head as well as the size of the surface area involved is best revealed with MRI. Additionally, in the era of cross sectional imaging a stage "0" seems obsolete. The guideline also addresses practically important considerations about the differential diagnosis of misleading MRI findings. This especially holds true for bone marrow oedema in the femoral head which may be misinterpreted. The differentiating features between FHN, transient bone marrow oedema and destructive arthropathy are discussed. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 26274557     DOI: 10.1055/s-0035-1545901

Source DB:  PubMed          Journal:  Z Orthop Unfall        ISSN: 1864-6697            Impact factor:   0.923


  4 in total

Review 1.  [Joint-preserving operative treatment of avascular necrosis of the femoral head].

Authors:  C Lüring; C Benignus; J Beckmann
Journal:  Orthopade       Date:  2018-09       Impact factor: 1.087

Review 2.  [Update of the German S3 guideline on atraumatic femoral head necrosis in adults].

Authors:  Andreas Roth; Johannes Beckmann; Klaus Bohndorf; Christian Heiß; Marcus Jäger; Stefan Landgraeber; Uwe Maus; Ulrich Nöth; Klaus M Peters; Christof Rader; Stephan Reppenhagen; Ulrich Smolenski; Ina Kopp; Markus Tingart
Journal:  Orthopade       Date:  2018-09       Impact factor: 1.087

Review 3.  [Imaging and classification of avascular femoral head necrosis].

Authors:  K Bohndorf; A Roth
Journal:  Orthopade       Date:  2018-09       Impact factor: 1.087

4.  Effectiveness of extracorporeal shock wave monotherapy for avascular necrosis of femoral head: A systematic review protocol of randomized controlled trial.

Authors:  Hua-Yu Tang; Yu Zhao; Yu-Zhi Li; Tian-Shu Wang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.